These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 15844307

  • 1. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.
    Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
    [Abstract] [Full Text] [Related]

  • 2. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
    Horm Res; 2004 Mar; 62(5):227-32. PubMed ID: 15477693
    [Abstract] [Full Text] [Related]

  • 3. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J, Barceló B.
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [Abstract] [Full Text] [Related]

  • 4. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [Abstract] [Full Text] [Related]

  • 5. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 6. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S.
    Endocr J; 2015 Sep; 62(1):21-7. PubMed ID: 25273395
    [Abstract] [Full Text] [Related]

  • 7. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
    Kurahashi K, Endo I, Kondo T, Morimoto K, Yoshida S, Kuroda A, Aihara KI, Matsuhisa M, Nakajima K, Mizobuchi Y, Nagahiro S, Abe M, Fukumoto S.
    Intern Med; 2017 Sep 15; 56(18):2455-2461. PubMed ID: 28824054
    [Abstract] [Full Text] [Related]

  • 8. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug 15; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 9. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar 15; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun 15; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
    J Clin Endocrinol Metab; 2002 Oct 15; 87(10):4554-63. PubMed ID: 12364434
    [Abstract] [Full Text] [Related]

  • 13. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
    Abe T, Lüdecke DK.
    Eur J Endocrinol; 2001 Aug 15; 145(2):137-45. PubMed ID: 11454508
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].
    Gołkowski F, Buziak-Bereza M, Huszno B.
    Przegl Lek; 2006 Aug 15; 63(3):117-22. PubMed ID: 16967698
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F, Magony S, Julesz J.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F.
    Horm Metab Res; 2001 Oct 12; 33(10):618-24. PubMed ID: 11607883
    [Abstract] [Full Text] [Related]

  • 20. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
    Harinarayan CV.
    J Indian Med Assoc; 2004 May 12; 102(5):258, 260-1. PubMed ID: 15636029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.